代谢综合征、代谢合并症与早发性结直肠癌风险
在18-64岁商业医保人群中开展巢式病例对照研究,发现代谢综合征与早发性结直肠癌风险升高相关(OR 1.25),风险随代谢合并症数目增加而升高(趋势P<0.001),该关联由近端和远端结肠癌驱动,而非直肠癌。
要点
- 代谢综合征与早发性结直肠癌风险升高相关,OR 1.25(95%CI 1.09-1.43)。
- 代谢合并症数目越多,早发性结直肠癌风险越高(趋势P<0.001)。
- 关联由近端和远端结肠癌驱动,直肠癌无显著关联。
核心结论
- 代谢紊乱与早发性结直肠癌风险升高相关,由近端和远端结肠癌驱动,可能部分解释了早发性结直肠癌发病率的上升。
研究设计与样本
- 在IBM MarketScan Commercial Database(2006-2015)18-64岁参与者中开展巢式病例对照研究,病例为病理学家编码ICD-9-CM识别的初发结直肠癌,对照按频率匹配。
- 代谢综合征定义为肥胖、高血压、高脂血症和高血糖/2型糖尿病中≥3项条件同时存在,基于ICD-9-CM编码和药物使用确定。
- 采用多变量logistic回归估计OR和95%CI。
主要发现
- 代谢综合征与早发性结直肠癌风险升高相关(n=4673;多变量校正OR 1.25;95%CI 1.09-1.43),与50-64岁诊断的结直肠癌相似(n=14928;OR 1.21;95%CI 1.15-1.27)。
- 与无代谢合并症者相比,有1、2或≥3项合并症者早发性结直肠癌风险分别升高9%(OR 1.09;95%CI 1.00-1.17)、12%(OR 1.12;95%CI 1.01-1.24)和31%(OR 1.31;95%CI 1.13-1.51)(趋势P<0.001)。
- 1或2项代谢合并症与50-64岁诊断的结直肠癌无关联。
- 上述正关联由近端结肠癌(每项条件OR 1.14;95%CI 1.06-1.23)和远端结肠癌(OR 1.09;95%CI 1.00-1.18)驱动,直肠癌无关联(OR 1.03;95%CI 0.97-1.09)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Factors that lead to metabolic dysregulation are associated with increased risk of early-onset colorectal cancer (CRC diagnosed under age 50). However, the association between metabolic syndrome (MetS) and early-onset CRC remains unexamined. DESIGN: We conducted a nested case-control study among participants aged 18-64 in the IBM MarketScan Commercial Database (2006-2015). Incident CRC was identified using pathologist-coded International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, and controls were frequency matched. MetS was defined as presence of ≥3 conditions among obesity, hypertension, hyperlipidaemia and hyperglycaemia/type 2 diabetes, based on ICD-9-CM and use of medications. Multivariable logistic regressions were used to estimate ORs and 95% CIs. RESULTS: MetS was associated with increased risk of early-onset CRC (n=4673; multivariable adjusted OR 1.25; 95% CI 1.09 to 1.43), similar to CRC diagnosed at age 50-64 (n=14 928; OR 1.21; 95% CI 1.15 to 1.27). Compared with individuals without a metabolic comorbid condition, those with 1, 2 or ≥3 conditions had a 9% (1.09; 95% CI 1.00 to 1.17), 12% (1.12; 95% CI 1.01 to 1.24) and 31% (1.31; 95% CI 1.13 to 1.51) higher risk of early-onset CRC (ptrend <0.001). No associations were observed for one or two metabolic comorbid conditions and CRC diagnosed at age 50-64. These positive associations were driven by proximal (OR per condition 1.14; 95% CI 1.06 to 1.23) and distal colon cancer (OR 1.09; 95% CI 1.00 to 1.18), but not rectal cancer (OR 1.03; 95% CI 0.97 to 1.09). CONCLUSIONS: Metabolic dysregulation was associated with increased risk of early-onset CRC, driven by proximal and distal colon cancer, thus at least in part contribute to the rising incidence of early-onset CRC.
引用
- Chen H, Zheng X, Zong X, et al. Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer. Gut. 2020. PMID: 33037055. doi:10.1136/gutjnl-2020-321661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。